DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif., March 27, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: ERN Source Type: news